Skip to content
10-K

Annual Report

APELLIS PHARMACEUTICALS, INC.

0001193125-26-065179

← back to feed
Filed
Feb 24, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 17, 2026 127.83M sh
Shares Diluted FY 2025 · Dec 31, 2025 129.86M sh
Shares Diluted FY 2025 · Dec 31, 2024 123.91M sh
Capex FY 2025 · Dec 31, 2025 $313K
Capex FY 2025 · Dec 31, 2024 $403K
Operating Cash Flow FY 2025 · Dec 31, 2025 $45.33M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$87.87M
Cash And Equivalents FY 2025 · Dec 31, 2025 $466.23M
Cash And Equivalents FY 2025 · Dec 31, 2024 $411.29M
Stockholders Equity FY 2025 · Dec 31, 2025 $370.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $228.54M
Current Liabilities FY 2025 · Dec 31, 2025 $323.6M
Current Liabilities FY 2025 · Dec 31, 2024 $185.51M
Total Liabilities FY 2025 · Dec 31, 2025 $705.11M
Total Liabilities FY 2025 · Dec 31, 2024 $656.51M
Current Assets FY 2025 · Dec 31, 2025 $1.01B
Current Assets FY 2025 · Dec 31, 2024 $788.95M
Total Assets FY 2025 · Dec 31, 2025 $1.08B
Total Assets FY 2025 · Dec 31, 2024 $885.05M
Eps Diluted FY 2025 · Dec 31, 2025 $0.20
Eps Diluted FY 2025 · Dec 31, 2024 −$1.60
Eps Basic FY 2025 · Dec 31, 2025 $0.18
Eps Basic FY 2025 · Dec 31, 2024 −$1.60
Sga Expense FY 2025 · Dec 31, 2025 $550.27M
Sga Expense FY 2025 · Dec 31, 2024 $501.05M
Sga Expense FY 2025 · Dec 31, 2023 $500.82M
Rd Expense FY 2025 · Dec 31, 2025 $295.85M
Rd Expense FY 2025 · Dec 31, 2024 $327.57M
Net Income FY 2025 · Dec 31, 2025 $22.39M
Net Income FY 2025 · Dec 31, 2024 −$197.88M
Operating Income FY 2025 · Dec 31, 2025 $55.43M
Operating Income FY 2025 · Dec 31, 2024 −$164.98M
Revenue FY 2025 · Dec 31, 2025 $1B
Revenue FY 2025 · Dec 31, 2024 $781.37M